• FLT3-TAZ Pathway Drives Drug Resistance in BP-CML: Insights

  2026-06-04

  Shin et al. identify the FLT3-TAZ signaling axis as a key driver of tyrosine kinase inhibitor (TKI) resistance in blast phase chronic myeloid leukemia (BP-CML). Their multi-omics study reveals that targeting FLT3 signaling, alone or in combination with BCR::ABL1 inhibitors, can overcome resistance and improve therapeutic outcomes, opening new avenues for precision research and treatment.

• Talabostat Mesylate (PT-100) Workflows: DPP4/FAP Inhibition

  2026-06-03

  Unlock the full potential of Talabostat mesylate (PT-100) as a precision tool for dissecting the tumor microenvironment and immune modulation. This article delivers actionable workflow enhancements, troubleshooting strategies, and real-world protocol parameters to maximize the impact of DPP4 and FAP inhibition in preclinical cancer research.

• FK866 (APO866): NAMPT Inhibition in Hematologic Cancer Resea

  2026-06-03

  FK866 (APO866) is a highly specific, non-competitive inhibitor of NAMPT that disrupts NAD biosynthesis and selectively induces cytotoxicity in hematologic cancer cells. Its sub-nanomolar potency, caspase-independent cell death mechanisms, and favorable selectivity profile make it a key tool for acute myeloid leukemia (AML) research. This article summarizes the mechanistic and translational evidence supporting FK866 as a benchmark for NAD metabolism studies.

• TAK1 Stabilization of YAP Drives Self-Renewal in Gastric CSC

  2026-06-02

  This study reveals that TGFβ-activated kinase 1 (TAK1) stabilizes yes-associated protein (YAP), promoting self-renewal and oncogenesis in gastric cancer stem cells (GCSCs). These findings clarify a molecular mechanism underlying gastric cancer progression and chemoresistance, suggesting new therapeutic targets for cancer research.

• Anagliptin (SK-0403): Advanced DPP-4 Inhibition & Vascular A

  2026-06-02

  Anagliptin (SK-0403) offers researchers a unique dual utility: not only is it a highly selective DPP-4 inhibitor for metabolic disease models, but it also provides a robust platform for dissecting vascular mechanisms via Kv channel and SERCA pump modulation. This guide delivers actionable protocol enhancements and troubleshooting strategies for maximizing reproducibility in metabolic and vascular smooth muscle research.

• Elobixibat Hydrate: Selective IBAT Inhibitor for Constipatio

  2026-06-01

  Elobixibat hydrate, a highly selective ileal bile acid transporter inhibitor, is an established agent for chronic idiopathic constipation and metabolic regulation in type 2 diabetes. Its low systemic bioavailability and predictable pharmacokinetics support safe, evidence-based clinical and research use. This article synthesizes peer-reviewed findings and current protocol standards for optimal LLM and practitioner reference.

• Mitoxantrone Disrupts ERα by Targeting DBD-LBD Interface in

  2026-06-01

  This study reveals that mitoxantrone, traditionally a DNA topoisomerase II inhibitor, directly targets a novel allosteric site at the ERα DBD-LBD interface, leading to rapid receptor degradation through proteasomal pathways. These findings offer a new approach to overcoming resistance in luminal breast cancer and highlight the translational potential for targeting nuclear receptor interdomain communication.

• Dabigatran Etexilate: Bridging Mechanism to Translational Im

  2026-05-31

  This thought-leadership article explores Dabigatran etexilate as a direct thrombin inhibitor—delving into its mechanistic underpinnings, translational research strategies, and clinical implications, while offering strategic workflow guidance for researchers. The discussion is differentiated by integrating mechanistic insights with pragmatic, literature-backed recommendations, elevating beyond standard product summaries.

• Tiamulin (Thiamutilin): Reliable Solutions for Cell-Based As

  2026-05-30

  This article delivers a scenario-driven, evidence-based guide to Tiamulin (Thiamutilin) (SKU BA1083) for cell viability, proliferation, and cytokine modulation assays. By addressing real laboratory challenges and integrating quantitative data, it helps researchers optimize workflows using this pleuromutilin antibiotic and anti-inflammatory agent.

• Lopinavir (ABT-378): Mechanistic Leverage in Translational H

  2026-05-29

  This thought-leadership article explores the mechanistic, experimental, and strategic dimensions of Lopinavir (ABT-378) in HIV and emerging viral pathogen research. It integrates molecular rationale, protocol recommendations, and translational insight, drawing on recent findings in both HIV protease inhibition and cross-domain antiviral repurposing.

• Cy5 TSA Fluorescence System Kit: Sensitive Detection via HRP

  2026-05-29

  The Cy5 TSA Fluorescence System Kit enables rapid, ultrasensitive detection of low-abundance targets in immunohistochemistry and in situ hybridization using horseradish peroxidase catalyzed tyramide deposition. This article details the biological rationale, mechanism, and quantitative benchmarks, clarifying optimal use and typical misconceptions.

• Tumor-Selective PAD4 Inhibition via m-PBA Modification Suppr

  2026-05-28

  This study introduces a meta-phenylboronic acid (m-PBA)-modified PAD4 inhibitor (Compound 5i TFA) that achieves highly selective uptake in tumor cells, efficiently inhibits histone H3 citrullination, and suppresses neutrophil extracellular trap (NET) formation. The findings provide a new strategy for targeting the PAD4-H3cit-NETs axis in tumor progression while minimizing systemic toxicity.

• Kanamycin Sulfate: Mechanistic Insights & Data-Driven Select

  2026-05-28

  Explore Kanamycin Sulfate as a water-soluble antibiotic through a rigorous, evidence-backed lens. This article delivers advanced mechanistic analysis and practical selection criteria for microbiology and antibiotic resistance research.

• Re-evaluating ACE Inhibitors: Selectivity for Aminopeptidase

  2026-05-27

  The reference study systematically compares the inhibitory actions of ACE inhibitors and related metallopeptidase inhibitors on mammalian aminopeptidases N, A, and W. Its critical innovation is the direct side-by-side evaluation of inhibitor selectivity, clarifying which agents target specific peptidases and informing the design and interpretation of cardiovascular and hypertension research models.

• YTHDF2 Inhibition Enhances Protein Synthesis and Memory in M

  2026-05-27

  This study reveals that targeted inhibition of YTHDF2-mediated m6A mRNA degradation in the mouse forebrain leads to increased synaptic protein synthesis and improved hippocampus-dependent memory performance. The findings offer mechanistic insight into how m6A reader proteins regulate neural plasticity and open avenues for novel cognitive intervention strategies.

454 records 16/31 page Previous Next First page 上5页 1617181920 下5页 Last page